Morgan Stanley starts Certara at 'equal weight'

Morgan Stanley initiates coverage of drug development software provider Certara CERT.O with an "equal weight" rating

"A key focus for the company is biosimulation, where Certara's platforms are designed to optimize drug design and testing" - Brokerage

Morgan Stanley says CERT has a market-leading platform and generates strong recurring revenues with significant cross-selling opportunities

Brokerage PT remains unchanged at $16, a ~39.3% upside on the stock's last close

Five of 11 brokerages rate the stock "buy" or higher, six "hold"; their median PT is $16 - LSEG data

As of last close, stock up ~7.9% YTD